Waldenstrom’s macroglobulinaemia recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:15:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Waldenstrom’s macroglobulinaemia recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies https://clinicaltrials.eu/trial/study-of-bgb-16673-in-combination-with-drug-therapy-for-patients-with-relapsed-or-refractory-b-cell-malignancies/ Thu, 30 Apr 2026 13:07:57 +0000 https://clinicaltrials.eu/trial/study-of-bgb-16673-in-combination-with-drug-therapy-for-patients-with-relapsed-or-refractory-b-cell-malignancies/ This clinical trial is studying treatments for B-cell malignancies that have returned or not responded to previous treatments. The study will test different combinations of medications, including BGB-16673, zanubrutinib, sonrotoclax, mosunetuzumab, obinutuzumab, and glofitamab. The purpose is to find safe and effective treatment combinations for patients whose cancer has come back or did not respond to earlier treatments.

The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion (given directly into a vein) or subcutaneous injection (given under the skin). The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause.

Throughout the study, doctors will monitor patients’ health, check how well the treatment is working, and track any side effects. They will look at how many patients respond to treatment and how long the response lasts. For some patients, they will also measure the amount of cancer cells remaining in the blood or bone marrow after treatment.

]]> A study to evaluate the effectiveness of epcoritamab in patients with Waldenström’s macroglobulinemia that has returned or has not responded to previous treatments. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-epcoritamab-in-patients-with-waldenstrom-s-macroglobulinemia-that-has-returned-or-has-not-responded-to-previous-treatments/ Wed, 29 Apr 2026 15:09:24 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-epcoritamab-in-patients-with-waldenstrom-s-macroglobulinemia-that-has-returned-or-has-not-responded-to-previous-treatments/ This study is being conducted to investigate the effects of a medication called epcoritamab (GEN3013) in people with Waldenstrom’s macroglobulinemia. This is a rare type of blood cancer where the body produces too much of a specific protein. The study focuses on patients with relapsed or refractory disease, which means the cancer has either returned after a period of improvement or has not responded to previous medical treatments.

The investigation is divided into two parts to first determine the most appropriate amount of the medicine to give and then to see how well it works. The medication is administered as a subcutaneous injection, which is a type of injection given into the fatty tissue just under the skin. Participants will receive the treatment for a series of cycles to monitor how the disease responds over time.

]]> Study of Acalabrutinib for Patients with Waldenström Macroglobulinemia https://clinicaltrials.eu/trial/study-of-acalabrutinib-for-patients-with-waldenstrom-macroglobulinemia/ Wed, 29 Apr 2026 15:00:30 +0000 https://clinicaltrials.eu/trial/study-of-acalabrutinib-for-patients-with-waldenstrom-macroglobulinemia/ This clinical trial is focused on studying Waldenström Macroglobulinemia, a rare type of cancer that affects white blood cells. The treatment being tested in this study is called acalabrutinib, which is available in two forms: 100 mg film-coated tablets and 100 mg hard capsules. The purpose of the study is to evaluate how well acalabrutinib works in treating patients with Waldenström Macroglobulinemia.

Participants in the study will take acalabrutinib orally, meaning they will swallow the tablets or capsules. The study is designed to observe the effects of the medication over a period of time, with regular check-ups to monitor the participants’ health and response to the treatment. The study aims to understand the overall response rate, which refers to how well the cancer responds to the treatment, as assessed by the study investigators.

Throughout the study, researchers will also look at other important factors such as the duration of response, progression-free survival, and overall survival. These terms refer to how long the treatment continues to work, how long patients live without the disease getting worse, and the overall lifespan of the participants, respectively. Additionally, the study will assess the safety of acalabrutinib by monitoring any side effects and how they affect the participants’ quality of life. The study is open-label, meaning both the researchers and participants know which treatment is being administered.

]]>